Posted on

Sienna Continues Platform Growth in Ontario

MARKHAM, Ontario, Sept. 17, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company“) (TSX: SIA) announced today that it has entered into a purchase agreement to acquire Stonemont On the Park (“Stonemont”), a 305-suite retirement residence in Ottawa, Ontario.

By sf-admin
Posted on

Invest in the Future of AI-Driven Real Estate: US Capital Global Securities Announces $33.1 Million Financing Opportunity for Kiteville

Explore an investment opportunity in Kiteville, a technology-enabled real estate platform acquiring and repositioning underperforming hospitality assets into flexible living communities. 

Explore an investment opportunity in Kiteville, a technology-enabled real estate platform acquiring and repositioning underperforming hospitality assets into flexible living communities.

By sf-admin
Posted on

National Advertising Division Finds Qualified Saffron Claim Supported; Recommends Alice Mushrooms Discontinue Zen-X Health Claim

As part of its monitoring program, BBB National Programs’ National Advertising Division examined Alice Mushrooms, LLC’s support for health claims made for its Zen-X mushroom-containing chocolate products. The National Advertising Division (NAD) recommended that Alice Mushrooms modify its Zen-X claim to make clear that the health benefit claim is limited to saffron. 

As part of its monitoring program, BBB National Programs’ National Advertising Division examined Alice Mushrooms, LLC’s support for health claims made for its Zen-X mushroom-containing chocolate products. The National Advertising Division (NAD) recommended that Alice Mushrooms modify its Zen-X claim to make clear that the health benefit claim is limited to saffron.

By sf-admin
Posted on

DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited

ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) — DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties.

By sf-admin
Posted on

Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) — Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on Thursday, September 10, 2026, by Zoar Limited (“PubCo”) in connection with the previously announced business combination (the “Business Combination”) with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley’s Bio Labs Limited) (“Zoar Labs”), which includes Impact’s preliminary proxy statement. The F-4 Registration Statement is available through the SEC’s website at www.sec.gov under the name “Zoar Limited”.

By sf-admin